190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech veröffentlicht am 31. März 2020 Ergebnisse des Geschäftsjahres und informiert zum operativen Fortschritt im vierten Quartal 2019
March 23, 2020 07:00 ET | BioNTech SE
MAINZ, Deutschland, March 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Dienstag, den 31. März 2020, die Ergebnisse des  Geschäftsjahres 2019...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine
March 17, 2020 02:02 ET | BioNTech SE
Companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection Collaboration aims to accelerate global development of BNT162, leveraging expertise and...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat
March 16, 2020 02:00 ET | BioNTech SE
Announces BNT162 vaccine program for the prevention of COVID-19 infectionAnticipates start of clinical testing for vaccine in late April 2020 Plans to assemble a global consortium of partners to...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech berichtet über rapide Fortschritte bei COVID-19-Impfstoff-Programm zur Bekämpfung der globalen Gesundheitsbedrohung
March 16, 2020 02:00 ET | BioNTech SE
BNT162-Impfstoffprogramm zur Prävention von COVID-19-Infektionen angekündigtBeginn der klinischen Studie im April 2020 erwartetPläne für ein globales Konsortium an Kollaborationspartnern im Kampf...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China
March 16, 2020 02:00 ET | BioNTech SE
BioNTech and Fosun Pharma will jointly conduct clinical trials of BNT162 in China, leveraging BioNTech’s proprietary mRNA vaccine technology and Fosun Pharma’s clinical development and...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech und Fosun Pharma arbeiten gemeinsam an der Entwicklung eines mRNA-basierten COVID-19-Impfstoffes in China
March 16, 2020 02:00 ET | BioNTech SE
BioNTech und Fosun Pharma werden gemeinsam klinische Studien für den Produktkandidaten BNT162 in China durchführen. Grundlage dafür bildet BioNTechs firmeneigene mRNA-Technologie sowie Fosuns...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech Announces Commencement of Public Offering of American Depositary Shares
February 03, 2020 16:46 ET | BioNTech SE
MAINZ, Germany, Feb. 03, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today, that it has filed a registration statement on Form F-1 with the United...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech plant öffentliches Angebot von American Depository Shares
February 03, 2020 16:46 ET | BioNTech SE
MAINZ, Deutschland, Feb. 03, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) hat heute die Registrierungsdokumente (Form F-1) bei der amerikanischen...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
January 16, 2020 07:30 ET | BioNTech SE; Neon Therapeutics, Inc.
Further expands BioNTech’s growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Continued Global Expansion
January 13, 2020 07:45 ET | BioNTech SE
MAINZ, Germany, Jan. 13, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the Supervisory Board has appointed Ryan Richardson to the Management...